A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease

Catherine L. Gallagher; Sterling C. Johnson; Barbara B. Bendlin; Moo K. Chung; James E. Holden; Terrence R. Oakes; Benjamin R. Brooks; Richard A. Konopacki; Selami Dogan; James H. Abbs; Guofan Xu; Robert J. Nickles; Robert W. Pyzalski; Onofre T. DeJesus; W. Douglas Brown

doi:10.1007/s11682-011-9124-5

A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease

Catherine L. Gallagher, Sterling C. Johnson, Barbara B. Bendlin, Moo K. Chung, James E. Holden, Terrence R. Oakes, Benjamin R. Brooks, Richard A. Konopacki, Selami Dogan, James H. Abbs, Guofan Xu, Robert J. Nickles, Robert W. Pyzalski, Onofre T. DeJesus, W. Douglas Brown

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Although [ ¹⁸F]fluoro-l-dopa [FDOPA] positron emission tomography (PET) has been used as a surrogate outcome measure in Parkinson's disease therapeutic trials, this biomarker has not been proven to reflect clinical status longitudinally. We completed a retrospective analysis of relationships between computerized sampling of motor performance, FDOPA PET, and clinical outcome scales, repeated over 4 years, in 26 Parkinson's disease (PD) patients and 11 healthy controls. Mixed effects analyses showed that movement time and tongue strength best differentiated PD from control subjects. In the treated PD cohort, motor performance measures changed gradually in contrast to a steady decline in striatal FDOPA uptake. Prolonged reaction and movement time were related to lower caudate nucleus FDOPA uptake, and abnormalities in hand fine force control were related to mean striatal FDOPA uptake. These findings provide evidence that regional loss of nigrostriatal inputs to frontostriatal networks affects specific aspects of motor function.

Original language	English (US)
Pages (from-to)	203-211
Number of pages	9
Journal	Brain Imaging and Behavior
Volume	5
Issue number	3
DOIs	https://doi.org/10.1007/s11682-011-9124-5
State	Published - Sep 2011
Externally published	Yes

Keywords

Ageing
Facial Muscles/*physiopathology
Fluorodopa
Motor control
Parkinson's disease
Positron emission tomography
Tongue/*physiopathology

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Neurology
Cognitive Neuroscience
Clinical Neurology
Cellular and Molecular Neuroscience
Psychiatry and Mental health
Behavioral Neuroscience

Access to Document

10.1007/s11682-011-9124-5

Cite this

Gallagher, C. L., Johnson, S. C., Bendlin, B. B., Chung, M. K., Holden, J. E., Oakes, T. R., Brooks, B. R., Konopacki, R. A., Dogan, S., Abbs, J. H., Xu, G., Nickles, R. J., Pyzalski, R. W., DeJesus, O. T., & Brown, W. D. (2011). A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease. Brain Imaging and Behavior, 5(3), 203-211. https://doi.org/10.1007/s11682-011-9124-5

Gallagher, CL, Johnson, SC, Bendlin, BB, Chung, MK, Holden, JE, Oakes, TR, Brooks, BR, Konopacki, RA, Dogan, S, Abbs, JH, Xu, G, Nickles, RJ, Pyzalski, RW, DeJesus, OT & Brown, WD 2011, 'A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease', Brain Imaging and Behavior, vol. 5, no. 3, pp. 203-211. https://doi.org/10.1007/s11682-011-9124-5

@article{d40c86b93e9e437bbe88a112ed815b73,

title = "A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease",

abstract = "Although [ 18F]fluoro-l-dopa [FDOPA] positron emission tomography (PET) has been used as a surrogate outcome measure in Parkinson's disease therapeutic trials, this biomarker has not been proven to reflect clinical status longitudinally. We completed a retrospective analysis of relationships between computerized sampling of motor performance, FDOPA PET, and clinical outcome scales, repeated over 4 years, in 26 Parkinson's disease (PD) patients and 11 healthy controls. Mixed effects analyses showed that movement time and tongue strength best differentiated PD from control subjects. In the treated PD cohort, motor performance measures changed gradually in contrast to a steady decline in striatal FDOPA uptake. Prolonged reaction and movement time were related to lower caudate nucleus FDOPA uptake, and abnormalities in hand fine force control were related to mean striatal FDOPA uptake. These findings provide evidence that regional loss of nigrostriatal inputs to frontostriatal networks affects specific aspects of motor function.",

keywords = "Ageing, Facial Muscles/*physiopathology, Fluorodopa, Motor control, Parkinson's disease, Positron emission tomography, Tongue/*physiopathology",

author = "Gallagher, {Catherine L.} and Johnson, {Sterling C.} and Bendlin, {Barbara B.} and Chung, {Moo K.} and Holden, {James E.} and Oakes, {Terrence R.} and Brooks, {Benjamin R.} and Konopacki, {Richard A.} and Selami Dogan and Abbs, {James H.} and Guofan Xu and Nickles, {Robert J.} and Pyzalski, {Robert W.} and DeJesus, {Onofre T.} and Brown, {W. Douglas}",

note = "Funding Information: Funding This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Science Research and Development Service [grant to C.G]; National Institutes of Health [grant number 1R29NS31612 to D.B] and University of Wisconsin Institute for Clinical and Translational Research, funded through a National Institutes of Health Clinical and Translational Science Award, [grant number 1UL1RR025011 to C.G.].",

year = "2011",

month = sep,

doi = "10.1007/s11682-011-9124-5",

language = "English (US)",

volume = "5",

pages = "203--211",

journal = "Brain Imaging and Behavior",

issn = "1931-7557",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease

AU - Gallagher, Catherine L.

AU - Johnson, Sterling C.

AU - Bendlin, Barbara B.

AU - Chung, Moo K.

AU - Holden, James E.

AU - Oakes, Terrence R.

AU - Brooks, Benjamin R.

AU - Konopacki, Richard A.

AU - Dogan, Selami

AU - Abbs, James H.

AU - Xu, Guofan

AU - Nickles, Robert J.

AU - Pyzalski, Robert W.

AU - DeJesus, Onofre T.

AU - Brown, W. Douglas

N1 - Funding Information: Funding This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Science Research and Development Service [grant to C.G]; National Institutes of Health [grant number 1R29NS31612 to D.B] and University of Wisconsin Institute for Clinical and Translational Research, funded through a National Institutes of Health Clinical and Translational Science Award, [grant number 1UL1RR025011 to C.G.].

PY - 2011/9

Y1 - 2011/9

N2 - Although [ 18F]fluoro-l-dopa [FDOPA] positron emission tomography (PET) has been used as a surrogate outcome measure in Parkinson's disease therapeutic trials, this biomarker has not been proven to reflect clinical status longitudinally. We completed a retrospective analysis of relationships between computerized sampling of motor performance, FDOPA PET, and clinical outcome scales, repeated over 4 years, in 26 Parkinson's disease (PD) patients and 11 healthy controls. Mixed effects analyses showed that movement time and tongue strength best differentiated PD from control subjects. In the treated PD cohort, motor performance measures changed gradually in contrast to a steady decline in striatal FDOPA uptake. Prolonged reaction and movement time were related to lower caudate nucleus FDOPA uptake, and abnormalities in hand fine force control were related to mean striatal FDOPA uptake. These findings provide evidence that regional loss of nigrostriatal inputs to frontostriatal networks affects specific aspects of motor function.

AB - Although [ 18F]fluoro-l-dopa [FDOPA] positron emission tomography (PET) has been used as a surrogate outcome measure in Parkinson's disease therapeutic trials, this biomarker has not been proven to reflect clinical status longitudinally. We completed a retrospective analysis of relationships between computerized sampling of motor performance, FDOPA PET, and clinical outcome scales, repeated over 4 years, in 26 Parkinson's disease (PD) patients and 11 healthy controls. Mixed effects analyses showed that movement time and tongue strength best differentiated PD from control subjects. In the treated PD cohort, motor performance measures changed gradually in contrast to a steady decline in striatal FDOPA uptake. Prolonged reaction and movement time were related to lower caudate nucleus FDOPA uptake, and abnormalities in hand fine force control were related to mean striatal FDOPA uptake. These findings provide evidence that regional loss of nigrostriatal inputs to frontostriatal networks affects specific aspects of motor function.

KW - Ageing

KW - Facial Muscles/physiopathology

KW - Fluorodopa

KW - Motor control

KW - Parkinson's disease

KW - Positron emission tomography

KW - Tongue/physiopathology

UR - http://www.scopus.com/inward/record.url?scp=79961027515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961027515&partnerID=8YFLogxK

U2 - 10.1007/s11682-011-9124-5

DO - 10.1007/s11682-011-9124-5

M3 - Article

C2 - 21556744

AN - SCOPUS:79961027515

SN - 1931-7557

VL - 5

SP - 203

EP - 211

JO - Brain Imaging and Behavior

JF - Brain Imaging and Behavior

IS - 3

ER -

A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this